Cerebrospinal fluid protein findings during prophylaxis and treatment of neuromeningosis in leukaemic patients

Scand J Clin Lab Invest. 1987 Dec;47(8):765-9.

Abstract

Methotrexate and Aracytin commonly employed in prophylaxis and treatment of leukaemic neuromeningosis, can induce neuromeningeal injury. Cerebrospinal fluid (CSF) protein disturbance may reflect the damage. In this study we have examined 141 CSF samples collected by lumbar puncture from 51 subjects: 15 normal controls and 36 leukaemic patients during the prophylaxis or the Central Nervous System (CNS) involvement treatment. In all the CSF samples, total proteins, IgG and IgA were examined. CSF total protein and albumin levels increased in the presence of leukaemic neuromeningosis and also after a prolonged CNS prophylaxis or therapy. The same behaviour was found in IgG levels. The IgA levels did not show any modification. We conclude that these parameters are not reliable indices of leukaemic CNS involvement.

MeSH terms

  • Adult
  • Aged
  • Albumins / cerebrospinal fluid
  • Central Nervous System Diseases / cerebrospinal fluid*
  • Central Nervous System Diseases / drug therapy
  • Central Nervous System Diseases / prevention & control
  • Cerebrospinal Fluid Proteins / analysis*
  • Cytarabine / administration & dosage*
  • Female
  • Humans
  • Immunoglobulin A / cerebrospinal fluid
  • Immunoglobulin G / cerebrospinal fluid
  • Injections, Spinal
  • Leukemia / cerebrospinal fluid*
  • Leukemia / drug therapy
  • Leukemia / prevention & control
  • Male
  • Meningeal Neoplasms / cerebrospinal fluid*
  • Meningeal Neoplasms / drug therapy
  • Meningeal Neoplasms / prevention & control
  • Methotrexate / administration & dosage*
  • Middle Aged

Substances

  • Albumins
  • Cerebrospinal Fluid Proteins
  • Immunoglobulin A
  • Immunoglobulin G
  • Cytarabine
  • Methotrexate